Deoxygenated Hemoglobin: Function and Role in the Body

Deoxygenated hemoglobin is not simply hemoglobin that has finished its job. Once it releases oxygen in your tissues, the molecule shifts into a different physical shape and takes on several active roles: it helps shuttle carbon dioxide back to the lungs, it triggers blood vessels to widen in oxygen-starved areas, and its magnetic properties make brain imaging possible. Far from being a spent taxi waiting for a return fare, deoxygenated hemoglobin is a working molecule with functions distinct from its oxygen-loaded counterpart.

Two Shapes, Two Jobs

Hemoglobin is a protein made of four interlocking subunits, each carrying an iron-containing heme group that can bind one molecule of oxygen. What makes hemoglobin remarkable is that it does not simply load and unload oxygen like a bucket. The whole molecule physically rearranges itself depending on how much oxygen it carries. When oxygen is bound, hemoglobin adopts what researchers call the R state (for “relaxed”). When oxygen is released, it snaps into the T state (for “tense”). In the T state, the subunits are held together by additional bonds that make it harder for oxygen to latch on again. In the R state, those constraints loosen, and the remaining empty sites become eager to grab oxygen.

This toggle is the foundation of hemoglobin’s usefulness. In the lungs, where oxygen is plentiful, the first oxygen molecule that binds makes it easier for the next three to follow, flipping hemoglobin toward the R state. In your tissues, where oxygen is scarce and carbon dioxide is abundant, the reverse happens: the first oxygen that leaves makes the remaining three more likely to detach, flipping hemoglobin toward the T state. The result is that hemoglobin loads efficiently in the lungs and unloads efficiently everywhere else.

How Carbon Dioxide and Acid Fine-Tune the Release

Active tissues do not just consume oxygen. They also produce carbon dioxide and acid as byproducts of metabolism. Deoxygenated hemoglobin is uniquely suited to deal with both. When the surrounding environment becomes more acidic or richer in carbon dioxide, hemoglobin’s grip on oxygen loosens further. This is the Bohr effect, and it acts as a local delivery booster: the harder a tissue is working, the more acid and carbon dioxide it generates, and the more oxygen hemoglobin dumps right where it is needed.

The flip side of that coin is the Haldane effect. Deoxygenated hemoglobin is much better at binding hydrogen ions and carbon dioxide than oxygenated hemoglobin is. So as hemoglobin releases oxygen in the tissues and shifts to the T state, it simultaneously picks up the metabolic waste products. Carbon dioxide hitches a ride partly by binding directly to hemoglobin and partly by being converted into bicarbonate, which is shuttled out of the red blood cell into the surrounding plasma. When this blood returns to the lungs, hemoglobin picks up oxygen again, shifts back to the R state, and sheds the carbon dioxide for you to exhale.

These two effects are really two sides of the same structural coin. The conformational change between T and R states creates reciprocal binding preferences: oxygen on one hand, acid and carbon dioxide on the other. Abolishing the Bohr effect in computational models dramatically increases hemoglobin’s oxygen affinity, which would be disastrous in the body because hemoglobin would hoard oxygen instead of releasing it to tissues.

A Molecule That Also Helps Determine Where It Is

Inside red blood cells, a small molecule called 2,3-DPG (or 2,3-BPG) binds in the central cavity of the hemoglobin tetramer, but only when hemoglobin is in the T state. By wedging itself between subunits, 2,3-DPG stabilizes the deoxygenated form and pushes hemoglobin to release even more oxygen. Your body can adjust 2,3-DPG levels in response to chronic oxygen stress. People who move to high altitude, for example, see a rise in red-cell organic phosphate levels within about a day, shifting hemoglobin’s behavior so more oxygen is released to tissues even though less is available in the air.

⁴

This is one of the fastest adaptive responses humans have to altitude. Long before the body ramps up red blood cell production (which takes weeks), it tweaks the chemistry inside existing red cells to make deoxygenated hemoglobin even more eager to dump oxygen.

Deoxygenated Hemoglobin as a Blood Vessel Opener

One of the more surprising discoveries about deoxygenated hemoglobin came in the early 2000s. Researchers found that deoxygenated hemoglobin acts as a nitrite reductase, meaning it converts circulating nitrite into nitric oxide, a potent signal that tells blood vessels to relax and widen. This is not a minor side reaction. In experiments on rat aortic rings and in the human forearm circulation, nitrite infusion during periods of low oxygen caused measurable vasodilation, and that effect depended on deoxyhemoglobin.

⁵

The elegance of this system is in its self-targeting. Hemoglobin’s nitrite reductase activity peaks when hemoglobin is about half-saturated with oxygen. That is roughly the saturation level at the boundary between well-oxygenated and oxygen-hungry tissue, exactly where you would want blood vessels to open up to increase flow.

⁶

A related mechanism involves S-nitrosylated hemoglobin. Hemoglobin can carry a nitric-oxide-derived group attached to a specific site on its protein chain. When hemoglobin transitions from the oxygenated to the deoxygenated form, it releases this NO-derived group, contributing to local vasodilation where oxygen is running low.

⁷

In organ-donor studies, lower levels of S-nitrosylated hemoglobin in donor blood were associated with lower tissue oxygenation, consistent with the idea that this pathway genuinely matters for microvascular blood flow in humans.

⁸

The Bluish Tinge You Can See

Deoxygenated hemoglobin is darker than its oxygenated counterpart. Oxygenated blood is bright red; deoxygenated blood is a deep, dusky red that can make skin and mucous membranes look bluish when enough of it accumulates near the surface. This visible sign is called cyanosis. Contrary to what is sometimes taught, the blue color is produced by deoxygenated hemoglobin sitting in shallow capillaries and small veins just under the skin, not by deeper arteries.

⁹

Cyanosis can be central (affecting the tongue and lips, suggesting low arterial oxygen) or peripheral (affecting the fingers and toes, suggesting sluggish local circulation). Because the color depends on the absolute amount of deoxygenated hemoglobin rather than its percentage, a severely anemic person might never appear cyanotic even while dangerously low on oxygen, simply because there is not enough total hemoglobin to create the visible color change. This is one reason clinicians do not rely on cyanosis alone as a diagnostic sign.

How Medicine Reads the Deoxygenation Signal

The color difference between oxygenated and deoxygenated hemoglobin is not just visible to the naked eye. It extends into wavelengths of light that instruments can measure with precision. Pulse oximeters, the small clips placed on your finger during a hospital visit, work by shining two wavelengths of light through your fingertip. Oxygenated hemoglobin absorbs more near-infrared light, while deoxygenated hemoglobin absorbs more red light. By comparing the two signals, the device estimates what fraction of your hemoglobin is carrying oxygen.

¹⁰

Deoxygenated hemoglobin also has a property that oxygenated hemoglobin lacks: it is paramagnetic, meaning it is slightly attracted to magnetic fields. This is the physical basis of functional MRI. When neurons in a particular brain region become active, local blood flow increases by more than the increase in oxygen consumption. The result is a small drop in the local concentration of deoxygenated hemoglobin, which changes the magnetic environment just enough for an MRI scanner to detect. This blood-oxygenation-level-dependent (BOLD) signal is the workhorse of modern brain imaging research.

¹¹ The BOLD signal is driven primarily by changes in the local concentration of paramagnetic deoxygenated hemoglobin, combined with changes in blood flow and volume.¹²

When Deoxygenation Triggers Disease

In sickle cell disease, a single amino acid change in the hemoglobin molecule creates a variant called hemoglobin S. When hemoglobin S is oxygenated, it behaves relatively normally. But when it shifts to the deoxygenated T state, the altered surface of the molecule becomes sticky. Deoxygenated hemoglobin S molecules lock together into rigid polymer fibers inside the red blood cell, distorting the cell into the characteristic sickle shape.

¹³

These stiffened cells clog small blood vessels, causing pain crises and organ damage. The polymerization is driven specifically by the deoxygenated state: it is the T-state shape that exposes the sticky contact site. Anything that increases local deoxygenation (exercise, dehydration, cold, high altitude) can accelerate sickling. The self-assembly of deoxygenated sickle hemoglobin into ordered fibers has consequences that extend from the molecular level to the flow behavior of blood itself, stiffening red cells and disrupting circulation.

¹⁴

A different kind of problem arises with methemoglobin, a form in which the iron in hemoglobin’s heme group is oxidized to a state that cannot bind oxygen at all. While not exactly the same as normal deoxygenated hemoglobin, methemoglobin shares one critical feature: the affected heme sites are unable to deliver oxygen to tissues. Methemoglobin can form from exposure to certain drugs, chemicals, or genetic conditions, and at high enough levels it causes symptoms ranging from headache to coma. The diagnosis can be tricky because methemoglobin interferes with both pulse oximeter readings and blood gas measurements.

How Fetal Hemoglobin Steals Oxygen From Its Mother

Before birth, a fetus cannot breathe on its own. It gets oxygen from the mother’s blood across the placenta. The problem is that maternal hemoglobin has already picked up oxygen in the mother’s lungs and does not particularly want to let go. The fetal solution is to use a different hemoglobin, called hemoglobin F, that grips oxygen more tightly than the adult version.

This higher affinity is not about a fundamentally different heme group. It comes largely from the way fetal hemoglobin interacts with 2,3-DPG. In adult hemoglobin, 2,3-DPG binds in the central cavity and stabilizes the T state, encouraging oxygen release. Fetal hemoglobin has amino acid differences that weaken its interaction with 2,3-DPG, so the molecule is less easily nudged into the deoxygenated form.

¹⁵ Research has pinpointed that a single amino acid difference at a position that does not even directly contact 2,3-DPG is critical for this reduced binding, a reminder that protein shape changes can propagate through indirect structural effects.¹⁶

The net result at the placenta is a molecular tug-of-war that the fetus wins. Maternal hemoglobin, pushed toward the T state by the relatively low-oxygen environment of the placental interface, releases oxygen. Fetal hemoglobin, resistant to that same push, scoops it up. After birth, the baby gradually switches over to producing adult hemoglobin, a transition that is normally complete within the first several months of life.

Birds That Fly Over Everest

Bar-headed geese migrate over the Himalayas at altitudes above 7,000 meters, where the oxygen pressure is roughly a third of what it is at sea level. One of their key adaptations is a hemoglobin with unusually high oxygen affinity. A single amino acid substitution at a contact point between hemoglobin subunits creates a small gap in the deoxygenated form of the molecule, making the T state slightly less stable. The T state, being less tightly locked, more readily transitions to the oxygen-hungry R state even when oxygen levels are low.

¹⁷

Crystal structure studies confirmed that the rotation angle between subunits during the T-to-R transition is much smaller in bar-headed goose hemoglobin than in human hemoglobin, consistent with a less dramatically locked deoxygenated state.

¹⁸ More recent mutagenesis work has shown that the picture involves more than one mutation. While one substitution accounts for the major increase in oxygen affinity, at least two others make smaller contributions, and one of those comes with a side effect (faster breakdown of the heme group) that is compensated by yet another mutation at a nearby position.

¹⁹

These birds illustrate that the balance between the T and R states is not a universal constant. Evolution can tune it. A hemoglobin that spends less time in the deoxygenated state can be an advantage at extreme altitude, even if it means slightly less efficient oxygen unloading at the tissue level. The trade-off works because the primary bottleneck at 7,000 meters is loading oxygen in the lungs, not releasing it in the muscles.

Cold Bodies and a Tighter Grip

Temperature also shifts the balance between hemoglobin’s two states. When the body cools down, hemoglobin’s affinity for oxygen increases, which means deoxygenated hemoglobin becomes harder to produce. During surgical hypothermia at 25 °C, the P50 (the oxygen pressure at which hemoglobin is half-saturated) drops from its normal value near 27 mmHg to roughly 13 mmHg.

²⁰

On the surface, this sounds problematic: if hemoglobin holds onto oxygen more tightly, tissues might not get what they need. In practice, the picture is more nuanced. Hypothermia also slashes metabolic demand. During deep cooling to 18 °C, oxygen consumption and extraction drop by more than half their baseline values, and a larger share of the body’s oxygen needs can be met by oxygen dissolved directly in plasma rather than carried by hemoglobin.

²¹

In animal experiments, hypothermia at 27 °C kept arterial blood oxygen content above 15 mL per 100 mL even at dangerously low inhaled oxygen levels, roughly three times the value that would be seen at normal body temperature under the same conditions. This is one of the reasons hypothermia is protective during certain cardiac and brain surgeries: the leftward shift of hemoglobin’s oxygen curve, which keeps more hemoglobin in the oxygenated form, acts as a buffer against tissue damage when blood flow is deliberately reduced.

²²

Artificial Hemoglobin and the Problem of Going Cell-Free

For decades, researchers have tried to build hemoglobin-based oxygen carriers (HBOCs) that could substitute for donor blood in emergencies, battlefield medicine, or situations where compatible blood is unavailable. The appeal is obvious: a shelf-stable product that does not need refrigeration, carries no infection risk, and works in any blood type. The reality has been humbling. Despite multiple generations of HBOC designs, including cross-linked, polymerized, and encapsulated forms of hemoglobin, none has yet received clinical approval in the United States for routine use.

²³

A core difficulty is that hemoglobin outside a red blood cell behaves differently than hemoglobin inside one. Free hemoglobin scavenges nitric oxide from blood vessel walls, causing dangerous vasoconstriction and raising blood pressure. Without the red cell’s internal environment of 2,3-DPG, enzymes, and reducing agents, the hemoglobin molecule is also more prone to oxidation. Early HBOC trials ran into problems with heart attacks and kidney damage, and overly ambitious clinical designs did not help. Current research is focused on better encapsulation strategies and engineered hemoglobin variants that are less reactive with nitric oxide, but the fundamental challenge remains: deoxygenated hemoglobin’s role in vasodilation via nitrite reduction and NO release, described earlier, depends on hemoglobin being inside a red blood cell, where the reaction is spatially controlled. Take hemoglobin out of that context, and its vascular signaling goes haywire.

²⁴ ²⁵